Company Overview of Glycoregimmune, Inc.
Glycoregimmune, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. The company was incorporated in 2009 and is based in San Diego, California.
8954 Rio San Diego Drive
San Diego, CA 92108
Founded in 2009
Key Executives for Glycoregimmune, Inc.
Glycoregimmune, Inc. Key Developments
Similar Private Companies By Industry
|Enobia Canada Limited Partnership||United States|
|Ixion Biotechnology, Inc.||United States|
|Advanced Microbial Services Inc.||United States|
|Cytoprint Inc.||United States|
|HydraDx, Inc.||United States|
Recent Private Companies Transactions
April 2, 2015
To contact Glycoregimmune, Inc., please visit www.gribio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.